Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740630 · ClinicalTrials.gov registry record · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
A Phase 3 study of Chickenpox, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,840
- Enrollment target
- 5
- Study locations
NCT06740630 is a Phase 3 study of Chickenpox that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 1,840 participants, above the 432-participant average among 4 other Chickenpox trials with a reported enrollment target (326% higher). The trial reports 5 study locations across 4 states.
The verdict
NCT06740630, a Phase 3 study of Chickenpox, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,840 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted in healthy children aged 12 to 15 months, who have neither contracted varicella nor received a varicella vaccination.
Conditions Studied
Interventions
- BIOLOGICAL Investigational varicella vaccine_Lot 1
- BIOLOGICAL Investigational varicella vaccine_Lot 2
- BIOLOGICAL Investigational varicella vaccine_Lot 3
- BIOLOGICAL Marketed varicella vaccine_Lot 1
- BIOLOGICAL Marketed varicella vaccine_Lot 2
Study Locations (5)
Utah
- GSK Investigational Site - Layton
- GSK Investigational Site - Layton
Florida
- GSK Investigational Site - Tampa
Michigan
- GSK Investigational Site - Bingham Farms
Texas
- GSK Investigational Site - McAllen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,840 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2027-05-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06740630
The ClinicalTrials.gov registry entry for NCT06740630 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,840 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 432-participant average among 4 other Chickenpox trials with a reported enrollment target (326% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chickenpox appearing as the primary indexed condition, and to 5 interventions - of which Investigational varicella vaccine_Lot 1 is the first listed.
NCT06740630 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Utah, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06740630 about?
NCT06740630 is a clinical study titled "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age". The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an already approved varicella vaccine (VV) known as Varivax. The study will be c...
What is the current status of trial NCT06740630?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,840 participants. The study started on 2025-01-10. Estimated completion is 2027-05-13.
What conditions does trial NCT06740630 study?
This clinical trial studies the following conditions: Chickenpox.
What interventions are being tested in trial NCT06740630?
The interventions under investigation include: Investigational varicella vaccine_Lot 1 (BIOLOGICAL), Investigational varicella vaccine_Lot 2 (BIOLOGICAL), Investigational varicella vaccine_Lot 3 (BIOLOGICAL), Marketed varicella vaccine_Lot 1 (BIOLOGICAL), Marketed varicella vaccine_Lot 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06740630?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06740630 being conducted?
This trial has 5 study locations across Florida, Michigan, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chickenpox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
RECRUITING · Phase 3
-
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
RECRUITING · Phase 3
-
Immune Response to Varicella-Zoster Vaccination and Infection
COMPLETED
-
Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.